Replimune, Roche to Develop RP3 in Colorectal Cancer, Hepatocellular Carcinoma
December 07 2022 - 7:44AM
Dow Jones News
By Colin Kellaher
Replimune Group Inc. on Tuesday said it inked a deal to work
with Swiss pharmaceutical company Roche Holding AG to advance
Replimune RP2/3 program in colorectal cancer and hepatocellular
carcinoma.
Replimune said Roche would share costs to develop RP3 in
combination with Roche's cancer drugs Tecentriq and Avastin in
third-line colorectal cancer and in second-line hepatocellular
carcinoma.
Replimune, a Woburn, Mass., clinical-stage biotechnology
company, said Roche would also supply Tecentriq and Avastin for
combination studies of RP3 in first-line hepatocellular carcinoma
and RP2 in third-line colorectal cancer.
Replimune, which has similar collaborations in place for its
lead candidate RP1 with Regeneron Pharmaceuticals Inc. and Bristol
Myers Squibb Co., said it is on track to initiate its Phase 2
development program with RP2/3 in the first half of 2023.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 07, 2022 07:29 ET (12:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Sep 2023 to Sep 2024